Intuitive Surgical stock (US46120E6023): Hits 12-month low as Leerink cuts price target

Intuitive Surgical shares fell to a 12-month low on May 11, 2026, after Leerink Partners reduced its price target from $622 to $573, citing valuation concerns in the robotic surgery leader.

Intuitive Surgical shares traded down 6.7% and hit a new 12-month low on May 11, 2026, according to MarketBeat as of May 11, 2026. The decline followed a downward revision by Leerink Partners, which reduced its price target to $573 from $622 while maintaining an outperform rating, according to the same source dated April 22, 2026.

As of: May 12, 2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Intuitive Surgical, Inc.
• Sector/industry: Medical technology, robotic-assisted surgery
• Headquarters/country: Sunnyvale, California, United States
• Core markets: Global hospitals and surgical centers
• Key revenue drivers: da Vinci surgical systems, instruments, service contracts
• Home exchange/listing venue: Nasdaq (ISRG)
• Trading currency: USD
• Market cap: $148.77 billion (as of May 11, 2026)
• P/E ratio: 50.92

Intuitive Surgical: Pioneer in robotic-assisted minimally invasive surgery

Intuitive Surgical, founded in 1995 and headquartered in Sunnyvale, California, is a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery. The company designs, manufactures, and markets the da Vinci surgical system, which translates a surgeon's hand movements into finer, scaled motions of small instruments inside the patient. This technology enables hospitals and surgical centers to perform complex procedures with greater precision, visualization, and control in the operating room.

The company maintains a dominant market position in robotic-assisted surgery, with near-monopoly status in this rapidly growing field for approximately two decades. Intuitive's business model centers on supplying systems, instruments, and related technologies to healthcare providers worldwide, with a focus on improving patient outcomes and reducing the invasiveness of surgical intervention.

Revenue model and recurring income streams

Intuitive generates the bulk of its high-margin recurring revenue through proprietary surgical instruments and service contracts. Every single procedure performed on a da Vinci system requires a new set of these proprietary, highly engineered instruments, creating a consistent revenue stream. This recurring revenue model has been a key driver of the company's financial performance and profitability.

Over the decade from 2015 to 2024, Intuitive maintained an annual revenue compound annual growth rate (CAGR) of approximately 15%, demonstrating incredibly consistent growth for a company of its size over such an extended period. The company continues to expand its product portfolio, including the ION platform for diagnostics, the SP platform for specialized single-port access, and the newer DV5 system for high-volume multi-port surgery.

Analyst perspective and valuation concerns

Leerink Partners' downward revision reflects broader valuation concerns in the medical technology sector. The analyst maintained an outperform rating despite cutting the price target, suggesting confidence in the company's long-term fundamentals while acknowledging near-term valuation pressures. The stock's P/E ratio of 50.92 and P/E/G ratio of 3.59 indicate that investors are pricing in significant future growth expectations.

Market position and competitive advantages

Intuitive Surgical's competitive moat rests on its proprietary technology, regulatory approvals, and the high switching costs associated with its installed base of da Vinci systems. The company continues to receive regulatory approval for additional surgical procedures, expanding the indications for its platforms. With approximately 270 SP platform systems installed globally and strong procedure growth of 38% in 2022, the company maintains leadership in a market with significant long-term growth potential.

Conclusion

Intuitive Surgical's 12-month low and the Leerink Partners price target reduction reflect near-term valuation pressures in the medical technology sector, despite the company's dominant market position and consistent historical growth. The stock's elevated P/E ratio suggests that current pricing reflects high growth expectations. Investors should monitor upcoming earnings reports, regulatory approvals for new procedures, and procedure volume trends as key indicators of the company's ability to justify its valuation premium in the robotic-assisted surgery market.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.